305 related articles for article (PubMed ID: 31545293)
1. Pioglitazone, an agonist of PPARγ, reverses doxorubicin-resistance in an osteosarcoma patient-derived orthotopic xenograft model by downregulating P-glycoprotein expression.
Higuchi T; Sugisawa N; Miyake K; Oshiro H; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Kline Z; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
Biomed Pharmacother; 2019 Oct; 118():109356. PubMed ID: 31545293
[TBL] [Abstract][Full Text] [Related]
2. PPARγ Agonist Pioglitazone in Combination With Cisplatinum Arrests a Chemotherapy-resistant Osteosarcoma PDOX Model.
Higuchi T; Yamamoto J; Sugisawa N; Tashiro Y; Nishino H; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
Cancer Genomics Proteomics; 2020; 17(1):35-40. PubMed ID: 31882549
[TBL] [Abstract][Full Text] [Related]
3. Pioglitazone modulates doxorubicin resistance in a in vivo model of drug resistant osteosarcoma xenograft.
Natarajan A; Ramachandran B; Gopisetty G; Jayavelu S; Sundersingh S; Rajkumar T
Naunyn Schmiedebergs Arch Pharmacol; 2021 Feb; 394(2):361-371. PubMed ID: 33015747
[TBL] [Abstract][Full Text] [Related]
4. Recombinant methioninase in combination with doxorubicin (DOX) overcomes first-line DOX resistance in a patient-derived orthotopic xenograft nude-mouse model of undifferentiated spindle-cell sarcoma.
Igarashi K; Kawaguchi K; Li S; Han Q; Tan Y; Murakami T; Kiyuna T; Miyake K; Miyake M; Singh AS; Eckardt MA; Nelson SD; Russell TA; Dry SM; Li Y; Yamamoto N; Hayashi K; Kimura H; Miwa S; Tsuchiya H; Singh SR; Eilber FC; Hoffman RM
Cancer Lett; 2018 Mar; 417():168-173. PubMed ID: 29306021
[TBL] [Abstract][Full Text] [Related]
5. Combining GRP78 suppression and MK2206-induced Akt inhibition decreases doxorubicin-induced P-glycoprotein expression and mitigates chemoresistance in human osteosarcoma.
Xia YZ; Yang L; Xue GM; Zhang C; Guo C; Yang YW; Li SS; Zhang LY; Guo QL; Kong LY
Oncotarget; 2016 Aug; 7(35):56371-56382. PubMed ID: 27486760
[TBL] [Abstract][Full Text] [Related]
6. Nilotinib reverses ABCB1/P-glycoprotein-mediated multidrug resistance but increases cardiotoxicity of doxorubicin in a MDR xenograft model.
Zhou ZY; Wan LL; Yang QJ; Han YL; Li D; Lu J; Guo C
Toxicol Lett; 2016 Sep; 259():124-132. PubMed ID: 27491883
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of tensin homolog deleted on chromosome ten (PTEN) by ciglitazone sensitizes doxorubicin-resistance leukemia cancer cells to treatment.
Mashayekhi S; Yousefi B; Tohidi E; Darband SG; Mirza-Aghazadeh-Attari M; Sadighparvar S; Kaviani M; Shafiei-Irannejad V; Kafil HS; Karimian A; Jadidi-Niaragh F; Majidinia M
J Cell Biochem; 2019 Sep; 120(9):15719-15729. PubMed ID: 31087712
[TBL] [Abstract][Full Text] [Related]
8. Dasatinib reverses the multidrug resistance of breast cancer MCF-7 cells to doxorubicin by downregulating P-gp expression via inhibiting the activation of ERK signaling pathway.
Chen T; Wang C; Liu Q; Meng Q; Sun H; Huo X; Sun P; Peng J; Liu Z; Yang X; Liu K
Cancer Biol Ther; 2015; 16(1):106-14. PubMed ID: 25482933
[TBL] [Abstract][Full Text] [Related]
9. Combination of CDK4/6 and mTOR Inhibitors Suppressed Doxorubicin-resistant Osteosarcoma in a Patient-derived Orthotopic Xenograft Mouse Model: A Translatable Strategy for Recalcitrant Disease.
Oshiro H; Tome Y; Miyake K; Higuchi T; Sugisawa N; Kanaya F; Nishida K; Hoffman RM
Anticancer Res; 2021 Jul; 41(7):3287-3292. PubMed ID: 34230123
[TBL] [Abstract][Full Text] [Related]
10. Histone deacetylase 6 regulated expression of IL-8 is involved in the doxorubicin (Dox) resistance of osteosarcoma cells via modulating ABCB1 transcription.
Cheng M; Cai W; Huang W; Chen Y; Wu Z; Luo P; Yan W
Eur J Pharmacol; 2018 Dec; 840():1-8. PubMed ID: 30273544
[TBL] [Abstract][Full Text] [Related]
11. Multiple pathways are involved in drug resistance to doxorubicin in an osteosarcoma cell line.
Rajkumar T; Yamuna M
Anticancer Drugs; 2008 Mar; 19(3):257-65. PubMed ID: 18510171
[TBL] [Abstract][Full Text] [Related]
12. The Combination of Cisplatinum and Doxorubicin Regressed Primary Osteosarcoma of the Breast in a PDOX Mouse Model.
Wu NF; Yamamoto J; Aoki Y; Masaki N; Samonte C; Wu J; Bouvet M; Hoffman RM
Anticancer Res; 2021 Oct; 41(10):4715-4718. PubMed ID: 34593419
[TBL] [Abstract][Full Text] [Related]
13. The combination of oral-recombinant methioninase and azacitidine arrests a chemotherapy-resistant osteosarcoma patient-derived orthotopic xenograft mouse model.
Higuchi T; Sugisawa N; Yamamoto J; Oshiro H; Han Q; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Tan Y; Kuchipudi S; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
Cancer Chemother Pharmacol; 2020 Feb; 85(2):285-291. PubMed ID: 31705268
[TBL] [Abstract][Full Text] [Related]
14. Eribulin Suppressed Cisplatinum- and Doxorubicin-resistant Recurrent Lung Metastatic Osteosarcoma in a Patient-derived Orthotopic Xenograft Mouse Model.
Kiyuna T; Tome Y; Miyake K; Murakami T; Oshiro H; Igarashi K; Kawaguchi K; Hsu J; Singh M; Li Y; Nelson S; Bouvet M; Singh SR; Kanaya F; Hoffman RM
Anticancer Res; 2019 Sep; 39(9):4775-4779. PubMed ID: 31519578
[TBL] [Abstract][Full Text] [Related]
15. Sequentially degradable hydrogel-microsphere loaded with doxorubicin and pioglitazone synergistically inhibits cancer stemness of osteosarcoma.
Cao J; Du X; Zhao H; Zhu C; Li C; Zhang X; Wei L; Ke X
Biomed Pharmacother; 2023 Sep; 165():115096. PubMed ID: 37421781
[TBL] [Abstract][Full Text] [Related]
16. Antiapoptotic and anti-inflammatory effects of Pparγ agonist, pioglitazone, reversed Dox-induced cardiotoxicity through mediating of miR-130a downregulation in C57BL/6 mice.
Pakravan G; Peymani M; Abedpoor N; Safaeinejad Z; Yadegari M; Derakhshan M; Nasr Esfahani MH; Ghaedi K
J Biochem Mol Toxicol; 2022 Jun; 36(6):e23041. PubMed ID: 35343021
[TBL] [Abstract][Full Text] [Related]
17. Reversal of P-glycoprotein-mediated multidrug resistance in SGC7901/VCR cells by PPARgamma activation by troglitazone.
Chen Q; Zhou J; Jiang C; Chen J
J Huazhong Univ Sci Technolog Med Sci; 2010 Jun; 30(3):326-31. PubMed ID: 20556576
[TBL] [Abstract][Full Text] [Related]
18. PPARγ-dependent anti-tumor and immunomodulatory actions of pioglitazone.
El-Sisi AE; Sokar SS; Salem TA; Abu Risha SE
J Immunotoxicol; 2015; 12(4):308-16. PubMed ID: 25425470
[TBL] [Abstract][Full Text] [Related]
19. Doxorubicin treatment modulates chemoresistance and affects the cell cycle in two canine mammary tumour cell lines.
Levi M; Salaroli R; Parenti F; De Maria R; Zannoni A; Bernardini C; Gola C; Brocco A; Marangio A; Benazzi C; Muscatello LV; Brunetti B; Forni M; Sarli G
BMC Vet Res; 2021 Jan; 17(1):30. PubMed ID: 33461558
[TBL] [Abstract][Full Text] [Related]
20. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]